Annotation Detail
Information
- Associated Genes
- FLT3
- Associated Variants
-
FLT3 ITD
FLT3 ITD - Associated Disease
- acute myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- Six children with relapsed or refractory FLT3-ITD-positive AML received initial therapy with sorafenib (alone or in combination with clofarabine and cytarabine). Four of the patients initially achieved morphological complete remission (bone marrow blasts <5%), however, 3 patients developed resistance within 14-37 weeks and and 1 required a bone marrow transplant. Two patients did not have any clinical response to sorafenib upon initial treatment.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1555
- Gene URL
- https://civic.genome.wustl.edu/links/genes/24
- Variant URL
- https://civic.genome.wustl.edu/links/variants/55
- Rating
- 1
- Evidence Type
- Predictive
- Disease
- Acute Myeloid Leukemia
- Evidence Direction
- Supports
- Drug
- Sorafenib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 23969938
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Sorafenib | Sensitivity | true |